The rounds this investor is named on, who it invests beside, and where it shows up.
Named on one round in the feed.
We are a Venture Capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus on ALS.
Venture capitalAmsterdam, The Netherlandsalsinvestmentfund.comSince 2026-11-11
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
VectorY Therapeutics A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases | Funding round Verified against 2 sources | $82.9M | 2026-11-11 | [ PART ] |